Member Info for Marty130

This government has made so many changes.

AIM shares are subject to Capital Gains Tax (CGT) like other investments, but their tax treatment depends on how they are held. You can avoid CGT on AIM share profits by holding them within a Stocks and Shares ISA. For Business Property Relief (BPR), which can exempt qualifying AIM shares from Inheritance Tax (IHT), these shares must be held for at least two years. From April 2026, the BPR on AIM shares will be reduced from 100% to 50%.

That's how it works, IMM is just the supplier.

ImmuPharma's potential profits depend on the successful development and commercialization of its P140 drug platform for conditions like lupus (SLE) and CIDP, with potential revenue streams from up-front payments, milestone payments, and ongoing royalties from commercialization deals in large markets. While the company faces increasing operational costs and a significant loss in its latest interim results, positive clinical data for the P140 platform and ongoing discussions with commercial partners suggest significant future financial upside if the late-stage drug assets reach the market, according to the company and analysts.

September 8/9 pence

October 15/20

November 25/30

December 35/40

January 70/90

February 150/200

March 250/300

The deal could well be more than 150 million, as a single injection could cost thousands.

No.

A very good friend of mine advised I invest in FTC, when it was 11p a share, space X signed deals and share price rocketed, lol..

At the time of AstraZeneca's acquisition in May 2006, Cambridge Antibody Technology (CAT) shares traded at 1,320 pence (£13.20) per share. This cash offer from AstraZeneca valued the company at £702 million and represented a 67% premium over CAT's closing price on the preceding Friday

To include R&D as usually happens..

Share prices always move upwards with deals in place.

Seriously doubt it will be three to five year's for any developments. A year from now will be a determining as regards where this company is likely to go. Most funds have been invested for a long time and will be keen for a significant turnaround sooner rather than later, especially now P140 has been announced.

As they only have six members of staff, and virtually no cash, how are they able to put together a marketing team and push their products forward?

ImmuPharma plc's top institutional shareholder as of June 1, 2025, was Hargreaves Lansdown Asset Management Ltd. with an 18.70% holding, followed by HBOS Investment Fund Managers Limited (10.72%) and Aberdeen Group Plc (10.36%). Significant individual and institutional shareholders as of late August 2025 include Lanstead Capital Investors LP (8.99%), Luca & Associates AG (4.40%), and Alora Pharmaceuticals (Avion) (2.18%).

Major Institutional Shareholders (as of June 1, 2025)

Hargreaves Lansdown Asset Management Ltd.: 18.70%

HBOS Investment Fund Managers Limited: 10.72%

Aberdeen Group Plc: 10.36%

Lanstead Capital L.P.: 8.99%

Will be derisked drastically in the coming months. This is turning into and reminding me of Filtronic/FTC.

We will see who's correct! A singular injection of p140 could cost high as a £1000

00..

Your post has some merrit but when you mention funds buying in they won't be involving lanstead, but rather buying thorough proxies around the world.

Mistake

The cost of dermal filler "P140" is not a recognized product; you may be referring to a specific brand or product name, or a different type of treatment. In the UK, typical dermal filler costs range from £150 to £500 per syringe, but this varies significantly by product, provider expertise, and location. To get an accurate price for "P140," you should contact a reputable clinic and ask about the specific product you're interested in.

Volumes have dropped off, possible signal of lower share price, going forward.